Evicenter
MarkdownMedical informationP&T meetings
Palazestrant (OP-1250)

Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Manufacturer
Olema Oncology
Last updated
256 sources

Section 3 of 6

Product information and disease description

543 evidence topics · 229 sources

Product description

Phase of product development

Regulatory status outside the United States

No evidence found.

Product information

Generic, brand name and therapeutic class of product
Brand name

No evidence found.

Dosage forms and strengths
Commercial dosage form and strength

No evidence found.

Average sales price and wholesale acquisition cost

Not applicable.

American hospital formulary service (AHFS), or other drug classification
AHFS class

No evidence found.

WHO ATC code

No evidence found.

Indication
Approved indication

No evidence found.

Pharmacology
Mechanism of action
Pharmacodynamics
Pharmacokinetics
Steady-state pharmacokinetic parameters at 60, 90, and 120 mg
Dose, once dailyTmax,ss, h, median [min–max]Cmin,ss, ng/mL, GeoMean (GeoCV%)Cmax,ss, ng/mL, GeoMean (GeoCV%)Cavg,ss, ng/mL, GeoMean (GeoCV%)AUC0–24,ss, ng*h/mL, GeoMean (GeoCV%)Accumulation ratio, Cmax,ssAccumulation ratio, AUC0–24,ss
60 mg“4.0”View highlighted excerpt for this quote“[1.00–6.00]”View highlighted excerpt for this quote“116 (50.3)”View highlighted excerpt for this quote“241 (47.1)”View highlighted excerpt for this quote“168 (45.2)”View highlighted excerpt for this quote“4030”View highlighted excerpt for this quote“2.25 (57.5)”View highlighted excerpt for this quote“2.94 (51.0)”View highlighted excerpt for this quote
90 mg“4.0”View highlighted excerpt for this quote“[1.00–6.00]”View highlighted excerpt for this quote“213 (92.7)”View highlighted excerpt for this quote“460 (77.4)”View highlighted excerpt for this quote“322 (82.1)”View highlighted excerpt for this quote“7720”View highlighted excerpt for this quote“3.55 (34.7)”View highlighted excerpt for this quote“5.12 (41.3)”View highlighted excerpt for this quote
120 mg“4.0”View highlighted excerpt for this quote“[1.00–6.00]”View highlighted excerpt for this quote“276 (41.6)”View highlighted excerpt for this quote“541 (37.4)”View highlighted excerpt for this quote“384 (37.9)”View highlighted excerpt for this quote“9210”View highlighted excerpt for this quote“1.96 (19.6)”View highlighted excerpt for this quote“4.76 (43.1)”View highlighted excerpt for this quote
Posted steady-state AUC by dose in the registry results
Dose, once dailyParticipants analyzedAUC0–24 at steady state, ng/mL*h, geometric meanGeometric coefficient of variation
30 mg“5”“1956”“33.0”
60 mg“26”“4014”“46.2”
90 mg“6”“7668”“82.4”
120 mg“77”“9163”“38.1”
150 mg“2”“12580”“27.3”
210 mg“6”“22439”“47.2”
300 mg“6”“25438”“40.2”
Effective half-life by dose during dose escalation
Dose, once dailyt1/2eff, h, GeoMeanGeoCV%
30 mg“54.7”“(26.0)”
60 mg“63.4”“(29.2)”
90 mg“72.7”“(54.1)”
120 mg“68.8”“(54.7)”
150 mg“61.6”“(23.6)”
210 mg“57.3”“(109.9)”
300 mg“51.0”“(61.7)”
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Treatment-emergent and treatment-related adverse events: phase 1/2 monotherapy at 60 and 120 mg
Adverse event, n (%)60 mg, any grade (n = 30)120 mg, any grade (n = 86)120 mg, grade 3120 mg, grade 4
TEAE: nausea“14 (46.7)”View highlighted excerpt for this quote“54 (62.8)”View highlighted excerpt for this quote“3 (3.5)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TEAE: vomiting“5 (16.7)”View highlighted excerpt for this quote“25 (29.1)”View highlighted excerpt for this quote“4 (4.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TEAE: fatigue“13 (43.3)”View highlighted excerpt for this quote“22 (25.6)”View highlighted excerpt for this quote“3 (3.5)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TEAE: neutropenia“2 (6.7)”View highlighted excerpt for this quote“21 (24.4)”View highlighted excerpt for this quote“3 (3.5)”View highlighted excerpt for this quote“6 (7.0)”View highlighted excerpt for this quote
TEAE: headache“7 (23.3)”View highlighted excerpt for this quote“17 (19.8)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TEAE: constipation“6 (20.0)”View highlighted excerpt for this quote“15 (17.4)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TEAE: diarrhea“6 (20.0)”View highlighted excerpt for this quote“12 (14.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TRAE: nausea“10 (33.3)”View highlighted excerpt for this quote“47 (54.7)”View highlighted excerpt for this quote“3 (3.5)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TRAE: vomiting“3 (10.0)”View highlighted excerpt for this quote“21 (24.4)”View highlighted excerpt for this quote“2 (2.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TRAE: fatigue“9 (30.0)”View highlighted excerpt for this quote“17 (19.8)”View highlighted excerpt for this quote“2 (2.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TRAE: neutropenia“0”View highlighted excerpt for this quote“18 (20.9)”View highlighted excerpt for this quote“3 (3.5)”View highlighted excerpt for this quote“5 (5.8)”View highlighted excerpt for this quote
Neutropenia: phase 1/2 monotherapy

“Treatment-related grade 4 neutropenia occurred in 5 (5.8%) patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Of the 6 patients with grade 4 neutropenia, 3 events resolved with a dose interruption (1 week) followed by a dose reduction (to 60 mg/day in 1 patient and to 90 mg/day in 2 patients); these patients continued treatment with no further neutropenia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“While grade 4 neutropenia events occurred approximately 6-8 weeks after initiation of palazestrant, these were managed with dose interruptions or discontinuations and/or with colony-stimulating factors, and following dose reductions, 3 patients were able to continue palazestrant with no further recurrences of neutropenia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The mechanism underlying neutropenia is unknown, and no corresponding trends were observed in preclinical studies of palazestrant (unpublished data).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Neutropenia, albeit at a lower frequency, has also been reported with fulvestrant, with grade ≥ 3 neutropenia observed in 1% to 2% of patients receiving fulvestrant monotherapy and rates of febrile neutropenia of 0 to 1% [30, 31].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Adverse events including neutropenia: combination with ribociclib
Related TEAE, n (%)120 mg + ribociclib, all grades (n = 56)120 mg, grade 3120 mg, grade 490 mg + ribociclib, all grades (n = 16)90 mg, grade 390 mg, grade 4
Neutropenia“47 (84%)”“28 (50%)”“5 (9%)”“13 (81%)”“9 (56%)”“2 (16%)”
WBC decrease“24 (43%)”“9 (16%)”“1 (2%)”“6 (38%)”“4 (25%)”“0”
Nausea“41 (73%)”“2 (4%)”“0”“11 (69%)”“1 (6%)”“0”
Fatigue“30 (54%)”“3 (5%)”“0”“9 (50%)”“0”“0”
Diarrhea“24 (43%)”“2 (4%)”“0”“4 (25%)”“0”“0”
Vomiting“21 (38%)”“1 (2%)”“0”“4 (25%)”“0”“0”
Electrocardiogram QT prolonged“16 (29%)”“4 (5%)”“0”“4 (25%)”“1 (6%)”“0”
AST increased“15 (27%)”“2 (4%)”“0”“3 (19%)”“0”“0”
Special populations
Nonclinical reproductive and developmental toxicology

No evidence found.

Hepatic and renal impairment: dedicated pharmacokinetic studies

No evidence found.

Central nervous system metastases: phase 2 cohort and exclusion from OPERA-01
Drug/Drug, drug/disease interactions
Effects of other drugs on Palazestrant
Dose-normalized palazestrant trough concentrations with and without ribociclib
StudyDose-normalized steady-state trough, geometric mean (geometric SD); n90% confidence interval
OP-1250-001, single agent“2.49 (48%); 172”“[2.35, 2.64]”
OP-1250-003, combination with ribociclib“3.35 (61%); 25”“[2.77, 4.06]”
Effects of Palazestrant on other drugs
Steady-state ribociclib parameters with and without palazestrant
Steady-state parameterRibociclib single agentRibociclib in combination with palazestrant
AUC0-24 ([h*ng/mL]/mg), GeoMean (GeoCV); N“23,800 (66%); 54”“25,400 (78%); 8”
Cmax (ng/mL/mg), GeoMean (GeoCV); N“1,820 (62%); 57”“1,860 (66%); 8”
Tmax (h), median (min–max); N“2.4 (0.68–7.8); 57”“4.0 (1.0–6.0); 8”
Dosing and administration
Dosage
Administration
Access and distribution
Specialty pharmacy or distribution network

No evidence found.

Co-prescribed/Concomitant therapies
Bone-modifying agents

No evidence found.

Effect of Palazestrant on quality measures
Product-specific effect on quality measures

No evidence found.

Product comparison
Palazestrant: class, dosing, and OPERA-01 population

“Palazestrant is a next-generation, orally bioavailable complete estrogen receptor antagonist (CERAN) and SERD with potent activity targeting the ER” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Palazestrant promotes ER degradation at levels similar to that of fulvestrant and greater than that of elacestrant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In Part 2, participants are randomized at a 1:1 ratio to receive once‑daily oral palazestrant (90 mg QD) or the investigator’s choice of SOC ET.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“OPERA-01 (NCT06016738) is a phase III study designed to evaluate the safety and efficacy of palazestrant monotherapy compared to SOC ET in patients with ER+, HER2– locally advanced or metastatic breast cancer, regardless of ESR1 mutation status, whose disease advanced following treatment with at least one ET in combination with a CDK4/6i.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“trials investigating the efficacy of the PROteolysis Targeting Chimera ER degrader (PROTAC), vepdegestrant, and the SERD, imlunestrant, showed progression-free survival (PFS) benefits specific to patients harboring ESR1 mutations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Palazestrant: phase 1/2 formulation, efficacy, and comparison with other estrogen receptor-targeting agents

“All patients received oral palazestrant capsules once daily, continuously in 28-day treatment cycles. In this first-in-human study, patients were required to fast for 2 h prior to and 1 h after each palazestrant dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Ongoing studies are using a tablet formulation, allowing drug administration in the fed state, and using anti-emetic medications when needed that may reduce frequency of nausea, vomiting, and fatigue” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“At 120 mg/day, the median progression-free survival was 4.8 months (95% CI, 3.5–7.1) overall and 5.6 months (95% CI, 4.8–NE) among patients with cancers with ESR1 mutations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Additionally, unlike with other SERDs that have reported rates of up to 45% for bradycardia and 56% for photopsia, the incidence of bradycardia and photopsia was lower with palazestrant (9% and 5%, respectively)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The CERAN/SERD mechanism of action of palazestrant is shared by fulvestrant, camizestrant and imlunestrant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Elacestrant, which is a selective ER modulator (SERM) and SERD, does not completely shut down ER signaling due to being an partial agonist and was also more active in cancers harboring ESR1 mutations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“although a direct comparison has not been performed” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Elacestrant (Orserdu): indication, regimen, EMERALD efficacy, and warnings
AttributePrescribing information
Indication“ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer as detected by an FDA-authorized test”“with disease progression following at least one line of endocrine therapy”
Mechanism“Elacestrant is an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα).”
Recommended dosage“The recommended dosage of ORSERDU is 345 mg taken orally with food once daily until disease progression or unacceptable toxicity occurs.”
Dosage forms and strengths“Tablets: Elacestrant 345 mg (equivalent to 400 mg elacestrant hydrochloride) and 86 mg (equivalent to 100 mg elacestrant hydrochloride)”
Pivotal trial“The efficacy of ORSERDU was evaluated in EMERALD (NCT03778931), a randomized, open-label, active-controlled, multicenter trial that enrolled 478 postmenopausal women and men with ER+/HER2- advanced or metastatic breast cancer of which 228 patients had ESR1 mutations.”
Prior therapy required“Patients were required to have disease progression on one or two prior lines of endocrine therapy, including one line containing a CDK4/6 inhibitor.”
Median PFS, ESR1-mutated, ORSERDU (N = 115), months (95% CI)“3.8 (2.2, 7.3)”
Median PFS, ESR1-mutated, fulvestrant or an aromatase inhibitor (N = 113), months (95% CI)“1.9 (1.9, 2.1)”
PFS hazard ratio, ESR1-mutated (95% CI)“0.55 (0.39, 0.77)”
Population without ESR1 mutations“An exploratory analysis of PFS in the 250 (52%) patients without ESR1 mutations showed a HR 0.86 (95% CI: 0.63, 1.19) indicating that the improvement in the ITT population was primarily attributed to the results seen in the ESR1 mutated population.”
Warnings and precautions“Dyslipidemia: ORSERDU may cause hypercholesterolemia and hypertriglyceridemia.”“Embryo-Fetal Toxicity: ORSERDU can cause fetal harm.”
Elacestrant (Orserdu): wholesale acquisition cost at launch
StrengthNDCPack sizeWAC (as of date of commercial availability)Date of commercial availability
86 mg“72187010103”“30 tablets”“$7,123.00”“2/3/2023”
345 mg“72187010203”“30 tablets”“$21,369.00”“2/3/2023”
Imlunestrant (Inluriyo): indications, regimen, EMBER-3 efficacy, and warnings
AttributePrescribing information
Indication, monotherapy“as monotherapy, for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy”
Indication, combination“in combination with abemaciclib for the treatment of adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy”
Mechanism“Imlunestrant is an estrogen receptor (ER) antagonist that binds to ERα.”
Recommended dosage“The recommended dosage of INLURIYO, as monotherapy or in combination with abemaciclib, is 400 mg orally once daily until disease progression or unacceptable toxicity.”
Administration“Take on an empty stomach at least 2 hours before food or 1 hour after food”
Dosage forms and strengths“INLURIYO tablets contain 200 mg imlunestrant”
Pivotal trial“The efficacy of INLURIYO was evaluated in EMBER-3 (NCT04975308), a randomized, open-label, active-controlled, multicenter trial that enrolled 874 adult patients with ER+, HER2- locally advanced or metastatic breast cancer of which 323 patients had ESR1 mutations (ESR1m), who were previously treated with an aromatase inhibitor either alone or in combination with a CDK4/6 inhibitor.”
Median PFS, ESR1m, INLURIYO (N=138), months (95% CI)“5.5 (3.9, 7.4)”
Median PFS, ESR1m, fulvestrant or exemestane (N=118), months (95% CI)“3.8 (3.7, 5.5)”
PFS hazard ratio, ESR1m (95% CI)“0.62 (0.46, 0.82)”
Overall population“A statistically significant difference in PFS in the overall population was not observed”
Median PFS, ESR1m, INLURIYO + abemaciclib (N=67) compared with INLURIYO (N=92), exploratory, months (95% CI)“11.1 (7.4, 13.7)”“5.5 (3.8, 7.2)”
PFS hazard ratio, ESR1m, INLURIYO + abemaciclib compared with INLURIYO (95% CI)“0.53 (0.35, 0.80)”
Warnings and precautions“Embryo-Fetal Toxicity: INLURIYO can cause fetal harm.”
Vepdegestrant (Veppanu): indication, regimen, VERITAC-2 efficacy, and warnings
AttributePrescribing information
Indication“VEPPANU is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.”
Mechanism“Vepdegestrant is a heterobifunctional protein degrader that binds to estrogen receptor (ER) and the E3 ligase cereblon (CRBN).”
Recommended dosage“The recommended dosage of VEPPANU is 200 mg taken orally once daily with food”
Dosage forms and strengths“Tablets: 100 mg and 200 mg”
Prior therapy required“Patients were required to have disease progression on 1 to 2 prior lines of endocrine therapy, including 1 line with a CDK4/6 inhibitor.”
Exclusions“Patients were excluded if they had received chemotherapy for advanced or metastatic disease or fulvestrant in any line of therapy”
Randomized comparison“Patients were randomized 1:1 to receive VEPPANU 200 mg orally once daily (N=313), or fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1 and then once monthly thereafter (N=311).”
Median PFS, ESR1-mutated, VEPPANU (N=136), months (95% CI)“5.0 (3.7, 7.4)”
Median PFS, ESR1-mutated, fulvestrant (N=134), months (95% CI)“2.1 (1.9, 3.5)”
PFS hazard ratio, ESR1-mutated (95% CI)“0.57 (0.42, 0.77)”
Warnings and precautions“VEPPANU can cause QT (QTc) interval prolongation”“In VERITAC-2, QTc interval prolongation was reported in 10% of patients; Grade 3 occurred in 1.6% of patients.”
Camizestrant (Etcamah): indication, regimen, SERENA-6 efficacy, and warnings
AttributePrescribing information
Indication“ETCAMAH in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test”
Approval pathway“This indication is approved under accelerated approval based on progression-free survival as measured from detection of ESR1 mutation”
Mechanism“Camizestrant is an estrogen receptor (ER) antagonist.”
Recommended dosage“The recommended dosage of ETCAMAH is 75 mg orally once daily, with or without food, until disease progression or unacceptable toxicity”
Dosage forms and strengths“Tablets: 75 mg.”
Pivotal trial setting“The ESR1 mutation status was assessed by ctDNA testing during first-line treatment with an AI in combination with a CDK4/6 inhibitor.”
Median PFS, ETCAMAH plus a CDK4/6 inhibitor (N = 157), months (95% CI)“16.0 (12.7, 18.2)”
Median PFS, AI plus a CDK4/6 inhibitor (N = 158), months (95% CI)“9.2 (7.2, 9.5)”
PFS hazard ratio (95% CI)“0.44 (0.31, 0.60)”
Boxed warning“ETCAMAH in combination with ribociclib, a QTc interval prolonging drug and a strong CYP3A inhibitor, or in combination with other QTc interval prolonging drugs, can increase the risk of Torsades de Pointes, other ventricular arrhythmias, and sudden death”
Warnings and precautions“Bradycardia: Monitor heart rate more frequently during the first 30 days.”
Fulvestrant (Faslodex): indications, regimen, CONFIRM efficacy, and warnings
AttributePrescribing information
Indication, monotherapy after endocrine therapy“HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.”
Indication, combination“HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.”
Mechanism“Fulvestrant is an estrogen receptor antagonist that binds to the estrogen receptor in a competitive manner with affinity comparable to that of estradiol and downregulates the ER protein in human breast cancer cells.”
Recommended dosage“FASLODEX 500 mg should be administered intramuscularly into the buttocks (gluteal area) slowly (1 - 2 minutes per injection) as two 5 mL injections, one in each buttock, on Days 1, 15, 29, and once monthly thereafter.”
Dosage forms and strengths“FASLODEX, an injection for intramuscular administration, is supplied as 250 mg/5 mL fulvestrant.”
Pivotal trial after endocrine therapy“A randomized, double-blind, controlled clinical trial (CONFIRM, NCT00099437) was completed in 736 postmenopausal women with advanced breast cancer who had disease recurrence on or after adjuvant endocrine therapy or progression following endocrine therapy for advanced disease.”
PFS hazard ratio, 500 mg compared with 250 mg (95% CI)“0.80 (0.68-0.94)”
Warnings and precautions“Risk of Bleeding: Use with caution in patients with bleeding diatheses, thrombocytopenia, or anticoagulant use.”“Injection Site Reaction: Use caution while administering FASLODEX at the dorsogluteal injection site due to the proximity of the underlying sciatic nerve.”
Capivasertib (Truqap): indication, regimen, CAPItello-291 efficacy, and warnings
AttributePrescribing information
Indication“TRUQAP, in combination with fulvestrant, is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alteration as detected by an FDA-authorized test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.”
Mechanism“Capivasertib is an inhibitor of all 3 isoforms of serine/threonine kinase AKT (AKT1, AKT2 and AKT3) and inhibits phosphorylation of downstream AKT substrates.”
Recommended dosage“The recommended dosage of TRUQAP, in combination with fulvestrant, is 400 mg orally twice daily (approximately 12 hours apart) with or without food, for 4 days followed by 3 days off.”
Dosage forms and strengths“Tablets: 160 mg and 200 mg”
Pivotal trial“The efficacy of TRUQAP with fulvestrant was evaluated in CAPItello-291 (NCT04305496), a randomized, double-blind, placebo-controlled, multicenter trial that enrolled 708 adult patients with locally advanced (inoperable) or metastatic HR-positive, HER2-negative (defined as IHC 0 or 1+, or IHC 2+/ISH-) breast cancer of which 289 patients had tumors with eligible PIK3CA/AKT1/PTEN-alterations.”
Median PFS, altered tumors, TRUQAP with fulvestrant (N=155), months (95% CI)“7.3 (5.5, 9.0)”
Median PFS, altered tumors, placebo with fulvestrant (N=134), months (95% CI)“3.1 (2.0, 3.7)”
PFS hazard ratio, altered tumors (95% CI)“0.50 (0.38, 0.65)”
Overall survival“At the prespecified final analysis of OS, there was no significant difference in OS between the TRUQAP with fulvestrant arm and the placebo with fulvestrant arm, with HR 0.83 (95% CI: 0.63, 1.10) in the PIK3CA/AKT1/PTEN-altered subgroup.”
Warnings and precautions“Hyperglycemia: TRUQAP can cause severe hyperglycemia, including diabetic ketoacidosis and fatal outcomes.”“Diarrhea: TRUQAP caused diarrhea in most patients.”“Cutaneous Adverse Reactions: Monitor for signs and symptoms of cutaneous adverse reactions.”
Capivasertib (Truqap): wholesale acquisition cost of blister packs
Gedatolisib (Revtorpyk): indication, regimen, VIKTORIA-1 efficacy, and warnings
AttributePrescribing information
Indication“REVTORPYK is a kinase inhibitor indicated in combination with fulvestrant, with or without palbociclib, for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.”
Mechanism“Gedatolisib is a kinase inhibitor of class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2, resulting in downstream inhibition of multiple effectors, including AKT.”
Recommended dosage“The recommended dosage of REVTORPYK is 180 mg as an intravenous infusion over 30 minutes once weekly on Days 1, 8, and 15 of every 28-day cycle, in combination with fulvestrant, with or without palbociclib, until disease progression or unacceptable toxicity.”
Dosage forms and strengths“REVTORPYK is supplied as a sterile, white to off-white lyophilized powder for injection containing 180 mg gedatolisib in a single-dose vial for reconstitution and further dilution.”
Prior therapy required“All patients were required to have progression on or after treatment with a CDK4/6 inhibitor and a non-steroidal aromatase inhibitor (AI) therapy.”
Median PFS, REVTORPYK + fulvestrant + palbociclib (N=131), months (95% CI)“9.3 (7.2, 16.6)”
Median PFS, REVTORPYK + fulvestrant (N=130), months (95% CI)“7.4 (5.5, 9.9)”
Median PFS, fulvestrant (N=131), months (95% CI)“2.0 (1.8, 2.3)”
Warnings and precautions“REVTORPYK can cause severe stomatitis, including ulcers and oral mucositis.”“In Study 1 of VIKTORIA-1, stomatitis occurred in 72% of patients treated with REVTORPYK with fulvestrant and palbociclib, including Grade 3 events in 22% of patients.”“Hyperglycemia: REVTORPYK can cause severe hyperglycemia.”

Place of product in therapy

Disease description

Definition and etiology
Previously treated disease: endocrine resistance definitions

“Primary endocrine resistance is defined as relapse while on the first two years of adjuvant endocrine therapy for early breast cancer, or progressive disease within the first six months of first line endocrine therapy-based treatment for advanced breast cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Secondary or acquired endocrine resistance encompasses all remaining clinical situations of endocrine resistance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The first subgroup, early acquired endocrine resistance , includes relapse while receiving endocrine therapy but after the first two years, relapse within one year of completing adjuvant endocrine therapy, or progressive disease occurring after at least six months, but less than twelve months, of first line endocrine therapy-based treatment for advanced breast cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The second subgroup, late acquired endocrine resistance , is defined as relapse more than twelve months after completing adjuvant endocrine therapy, or progressive disease after at least twelve months of first line endocrine therapy-based treatment for advanced breast cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Epidemiology
Incidence of Previously treated ER-positive HER2-negative advanced or metastatic breast cancer
U.S. share of cases that are HR-positive/HER2-negative, SEER 21, 2019 to 2023
SubtypePercent of cases
HR+/HER2-“70%”
HR-/HER2-“11%”
HR+/HER2+“9%”
HR-/HER2+“4%”
Unknown“6%”
U.S. stage distribution at diagnosis, SEER 21
Stage at diagnosisPercent of cases
Localized“64%”
Regional“27%”
Distant“6%”
Unknown“2%”
U.S. new metastatic female breast cancer cases, 2018 estimate and 2025 projection
MeasureBreast (female)
Number of new metastatic cancer cases, de novo (observed), 2018“15 800”View highlighted excerpt for this quote
Number of new metastatic cancer cases, de novo and recurrence (estimated), 2018“46 666”View highlighted excerpt for this quote
Projected number of new metastatic (de novo and recurrence) cancer cases, 2025“52 126”View highlighted excerpt for this quote
Prevalence of Previously treated ER-positive HER2-negative advanced or metastatic breast cancer
U.S. prevalence of previously treated ER-positive HER2-negative advanced disease

No evidence found.

Worldwide 5-year prevalence of breast cancer by continent, GLOBOCAN 2024
Natural history, survival, and mortality
U.S. 5-year relative survival by stage at diagnosis, SEER 21, 2016 to 2022
Stage at diagnosis5-year relative survival
Localized“100.0%”
Regional“87.5%”
Distant“33.8%”
Pathophysiology
Diagnosis
Clinical presentation - signs and symptoms
Long-term morbidity
Burden of Previously treated ER-positive HER2-negative advanced or metastatic breast cancer
Humanistic burden and health-related quality of life
Pain and EQ-5D-3L utility by metastatic site and pain severity in 739 participants in the United States and Europe
Economic burden and healthcare resource utilization
Economic impact of Previously treated ER-positive HER2-negative advanced or metastatic breast cancer on families
Economic impact of diagnostic testing
Advanced Diagnostic Laboratory Test status and initial-period payment for Guardant360 CDx and FoundationOne Liquid CDx

Approaches to treatment

Current treatment options and standard of care
Oral selective estrogen receptor degraders and estrogen receptor degraders
PI3K, AKT, and mTOR pathway inhibitors
CDK4/6 inhibitors after progression on a CDK4/6 inhibitor
Fulvestrant, aromatase inhibitors, and tamoxifen
PARP inhibitors for germline BRCA1 or BRCA2 variants
Antibody-Drug conjugates
Antibody-drug conjugate positioning and sequencing: ABC8 consensus 2026

“In the ADC landscape, DESTINY-Breast06 showed that T-DXd can be an option for patients with HER2-low disease when the decision to initiate cytotoxic therapy is made, now earlier in the treatment sequence, as first-line cytotoxic therapy after progression on endocrine therapy and for whom further endocrine therapy was considered unsuitable, based on a 5.1-month improvement in median PFS over physician's choice chemotherapy (HR: 0.62), OS showed no statistically significant improvement” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For patients with HER2 ultra-low disease, the available data remain limited and further evidence is required before a recommendation can be made.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In view of the modest PFS improvement, the absence of mature OS data, the side effect profile, and the availability of other treatment options, Dato-DXd in this setting is not a preferred option at present.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Sacituzumab govitecan has moved to a less favored position in this subtype following the negative results of ASCENT-07, which failed to demonstrate superiority over single-agent chemotherapy as first-line cytotoxic therapy in ER+/HER2-negative ABC (median PFS by BICR: 8.3 months in both arms; HR: 0.85)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the absence of validated predictive biomarkers and robust evidence from prospective clinical trials, routine sequencing of ADCs in this setting cannot currently be recommended.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Chemotherapy
Limitations of current therapies
Summary: limitations of endocrine and targeted therapies after a CDK4/6 inhibitor

The oral estrogen receptor degraders approved after progression on endocrine therapy (elacestrant, imlunestrant, and vepdegestrant) are indicated for ESR1-mutated disease, and each label directs selection of patients “based on the presence of ESR1 mutation(s)” in a plasma specimen. Without ESR1 mutations, the progression-free survival hazard ratio for elacestrant was 0.86 (95% CI 0.63 to 1.19) in 250 participants (52%) in EMERALD, and median progression-free survival in EMBER-3 was 5.6 months with imlunestrant and 5.7 months with standard therapy (hazard ratio 1.00). In ESR1-mutated tumors, the ABC8 consensus describes “modest absolute clinical benefit” across the oral SERDs, with hazard ratios generally in the 0.55 to 0.62 range. In EMERALD, median progression-free survival was 2.8 versus 1.9 months in the overall population and 3.8 versus 1.9 months in the ESR1 mutation cohort. In the control arms of VERITAC-2 and EMBER-3, median progression-free survival was 2.1 months with fulvestrant among 270 participants with ESR1 mutations and 3.8 months with standard therapy among participants with ESR1 mutations, respectively. In real-world studies after a first-line CDK4/6 inhibitor, the weighted average median progression-free survival was 3.9 months with single-agent endocrine therapy and 6.1 months with chemotherapy, and in a second cohort, median second-line real-world progression-free survival with endocrine monotherapy was 5.0 months (n = 27).

Fulvestrant 500 mg is administered as two 5 mL intramuscular injections on Days 1, 15, 29, and once monthly thereafter, and injection site pain was reported in 11.6% of participants in the fulvestrant 500 mg group. Hyperglycemia was reported in 65% of participants treated with alpelisib, and increased fasting glucose occurred in 37% of participants treated with capivasertib and 85% of participants treated with inavolisib; adverse events led to discontinuation in 25.0% of participants receiving alpelisib (4.2% with placebo) and 13.0% of participants receiving capivasertib (2.3% with placebo). Overall survival was not significantly improved with capivasertib plus fulvestrant (hazard ratio 0.83 in the PIK3CA/AKT1/PTEN-altered subgroup), alpelisib plus fulvestrant in the PIK3CA-mutated cohort (39.3 versus 31.4 months), everolimus plus exemestane (31.0 versus 26.6 months), abemaciclib plus fulvestrant (32.1 versus 24.6 months), or imlunestrant in ESR1-mutated disease (34.5 versus 23.1 months, boundary for significance not reached). The ABC8 consensus does not recommend rechallenge with a second oral SERD or a second PI3K/AKT/mTOR inhibitor outside clinical trials, and states that following progression on a CDK4/6 inhibitor “the optimal sequence remains undefined”.

Summary: limitations of PARP inhibitors, antibody-drug conjugates, and chemotherapy

Olaparib and talazoparib are indicated for germline BRCA-mutated, HER2-negative disease, and approximately 5% of all breast cancer patients carry a germline deleterious BRCA1 and/or BRCA2 mutation. Neither improved overall survival significantly over chemotherapy: median overall survival was 19.3 months with olaparib and 17.1 months with chemotherapy (hazard ratio 0.90; 0.86 in hormone receptor-positive participants), and the overall survival hazard ratio with talazoparib was 0.827 in hormone receptor-positive participants. Adjudicated drug-related interstitial lung disease or pneumonitis occurred in 12.1% of participants receiving trastuzumab deruxtecan in DESTINY-Breast04, and adjudicated interstitial lung disease or pneumonitis in 11.3% in DESTINY-Breast06; ocular adverse reactions occurred in 38% of participants treated with datopotamab deruxtecan in the pooled safety population; and grade 3 or higher treatment-related neutropenia occurred in 51% of participants receiving sacituzumab govitecan in TROPiCS-02. Overall survival with datopotamab deruxtecan was not significantly different from chemotherapy (hazard ratio 1.01), and the ABC8 consensus states that routine sequencing of antibody-drug conjugates in this setting “cannot currently be recommended”. In the TROPION-Breast01 control arm, single-agent chemotherapy produced a median progression-free survival of 4.9 months, with grade 3 or higher treatment-related adverse events in 44.7% of participants, and eribulin was not superior to capecitabine for overall survival (median 15.9 versus 14.5 months) or progression-free survival (4.1 versus 4.2 months).

Place in treatment, anticipated use, and care setting
Summary: anticipated place in therapy

Palazestrant has no approved indication. The company plans to submit a new drug application in 2027 for monotherapy in second- and third-line ER+/HER2- metastatic breast cancer and anticipates commercial launch in 2028. The FDA Fast Track designation covers ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. In OPERA-01, participants whose disease advanced after at least one endocrine therapy given with a CDK4/6 inhibitor are enrolled “regardless of ESR1 mutation status” and, in Part 2, randomized 1:1 to palazestrant 90 mg once daily or investigator's choice of standard-of-care endocrine therapy (fulvestrant, letrozole, anastrozole, or exemestane). The company states that “Palazestrant’s approval in ESR1 mutant and wild-type tumors in the 2/3L ER+/HER2- MBC setting would be paradigm-shifting”. The approved oral agents in the same setting, elacestrant, imlunestrant, and vepdegestrant, are each indicated only for ESR1-mutated disease after at least one line of endocrine therapy, and the NCCN guideline lists elacestrant, imlunestrant, or vepdegestrant for ESR1-mutated tumors, aromatase inhibitor monotherapy as a subsequent-line option, and fulvestrant with alpelisib or capivasertib for PIK3CA, AKT1, or PTEN alterations. The ESMO 2026 guideline states that at least two lines of endocrine-based therapy can be recommended before non-endocrine therapy in endocrine-sensitive disease and that a fulvestrant–CDK4/6 inhibitor switch or, to a lesser extent, fulvestrant monotherapy may be considered in the absence of targetable alterations. The ABC8 consensus recommends switching the endocrine mechanism of action when resistance emerges, reports oral SERD hazard ratios of 0.55 to 0.62 in ESR1-mutated tumors, and states that “Rechallenge with one oral SERD after progression on another is not recommended outside clinical trials”. In one cohort treated after first-line CDK4/6 inhibitor therapy, second-line treatment was cytotoxic chemotherapy in 29.7% of 839 participants, endocrine monotherapy in 12.4%, and continued CDK4/6 inhibitor in 36.0%. Palazestrant is taken orally once daily, whereas fulvestrant is given as two intramuscular injections every 28 days, with injections “mainly requiring in-office administration”. The company plans a field force of approximately 75 to 100 representatives “to cover U.S. breast oncologists” and is studying palazestrant with ribociclib in the first line in OPERA-02, with the goal of positioning it as the “endocrine therapy of choice in the first-line setting”.

Heterogeneity of treatment effect
Care management intervention strategies
Other product development or post-marketing obligations required by the FDA
Post-marketing requirements or commitments

Not applicable.

Ongoing post-approval monitoring
Post-approval monitoring requirements

Not applicable.

Expected outcomes of therapy